DE69808281D1 - Verwendung einer inhibitorsubstanz zur förderung der neuronalen regeneration - Google Patents

Verwendung einer inhibitorsubstanz zur förderung der neuronalen regeneration

Info

Publication number
DE69808281D1
DE69808281D1 DE69808281T DE69808281T DE69808281D1 DE 69808281 D1 DE69808281 D1 DE 69808281D1 DE 69808281 T DE69808281 T DE 69808281T DE 69808281 T DE69808281 T DE 69808281T DE 69808281 D1 DE69808281 D1 DE 69808281D1
Authority
DE
Germany
Prior art keywords
neuronal regeneration
promote neuronal
inhibitor substance
regeneration
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69808281T
Other languages
English (en)
Other versions
DE69808281T3 (de
DE69808281T2 (de
Inventor
Prof Dr Mueller
Dr Stichel-Gunkel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEURAXO BIOPHARMACEUTICALS GMBH, 40699 ERKRATH, DE
Original Assignee
NEURAXO BIOTEC GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8226794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69808281(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NEURAXO BIOTEC GmbH filed Critical NEURAXO BIOTEC GmbH
Application granted granted Critical
Publication of DE69808281D1 publication Critical patent/DE69808281D1/de
Publication of DE69808281T2 publication Critical patent/DE69808281T2/de
Publication of DE69808281T3 publication Critical patent/DE69808281T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
DE69808281T 1997-05-14 1998-05-13 Verwendung einer inhibitorsubstanz zur förderung der neuronalen regeneration Expired - Lifetime DE69808281T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97107846A EP0878480A1 (de) 1997-05-14 1997-05-14 Verfahren zur Förderung der Nerven-Regenerierung
EP97107846 1997-05-14
PCT/EP1998/002808 WO1998051708A1 (en) 1997-05-14 1998-05-13 A method for the improvement of neuronal regeneration

Publications (3)

Publication Number Publication Date
DE69808281D1 true DE69808281D1 (de) 2002-10-31
DE69808281T2 DE69808281T2 (de) 2003-01-16
DE69808281T3 DE69808281T3 (de) 2008-01-24

Family

ID=8226794

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69808281T Expired - Lifetime DE69808281T3 (de) 1997-05-14 1998-05-13 Verwendung einer inhibitorsubstanz zur förderung der neuronalen regeneration

Country Status (8)

Country Link
US (3) US20020115598A1 (de)
EP (2) EP0878480A1 (de)
AT (1) ATE224915T1 (de)
AU (1) AU7654298A (de)
DE (1) DE69808281T3 (de)
DK (1) DK0981549T4 (de)
ES (1) ES2180175T5 (de)
WO (1) WO1998051708A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0878480A1 (de) * 1997-05-14 1998-11-18 H.W. Prof. Dr. Müller Verfahren zur Förderung der Nerven-Regenerierung
US6200974B1 (en) 1997-10-24 2001-03-13 Zeneca Limited Phenanthroline derivatives
CN101664409A (zh) * 2001-12-06 2010-03-10 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
CN1602360A (zh) * 2001-12-06 2005-03-30 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
DE10314082A1 (de) * 2003-03-28 2004-10-21 Mcs Micro Carrier Systems Gmbh Biodegradierbares injizierbares Implantat
EP1937215A2 (de) * 2005-09-02 2008-07-02 Neuraxo Biopharmaceuticals GmbH Pharmazeutische zusammensetzung mit einem eisen-chelatbildner
WO2007048846A1 (de) * 2005-10-27 2007-05-03 Neuraxo Biopharmaceuticals Gmbh Verwendung von eisen chelatisierenden verbindungen, zyklisches adenosinmonophosphat erhöhende verbindungen oder kombinationen davon zur behandlung von axonalen läsionen im zns
EP2000134A1 (de) * 2007-06-06 2008-12-10 Neuraxo Biopharmaceuticals GmbH Verwendung einer Substanz zur Behandlung von Verletzungen des peripheren Nervensystems
US9649381B2 (en) 2013-11-06 2017-05-16 Wayne State University Transporter protein-coupled nanodevices for targeted drug delivery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4214000A (en) † 1978-10-30 1980-07-22 Johnson & Johnson Zinc salt of all-trans-retinoic acid for the treatment of acne
DE3002989A1 (de) * 1980-01-29 1981-07-30 Hoechst Ag, 6000 Frankfurt Hydroxyphenyl-thiazol, -thiazolin und -thiazolidin-carbonsaeuren, verfahren zu ihrer herstellung und ihre verwendung zur beeinflussung des kollagenstoffwechsels
CA1251729A (en) * 1982-05-19 1989-03-28 Steffen Gay In vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
DE3432094A1 (de) * 1984-08-31 1986-03-06 Hoechst Ag, 6230 Frankfurt Ester der pyridin-2,4- und -2,5- dicarbonsaeure als arzneimittel zur inhibierung der prolin- und lysinhydroxylase
US5021404A (en) † 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
WO1993019783A1 (en) * 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
JPH06103773A (ja) † 1992-09-16 1994-04-15 Hitachi Ltd 半導体記憶装置
CA2117889A1 (en) * 1993-02-11 1994-08-18 Martin E. Schwab A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
DE69429539T2 (de) * 1993-10-15 2002-09-05 Thomas Jefferson University, Philadelphia Inhibierung der synthese von extrazellulärer matrix mittels "antisense"-zusammensetzungen, die gegen c-myc gerichtet sind
CA2173731A1 (en) * 1993-11-08 1995-05-18 Martin Grumet Neuron-glia cell adhesion molecule, ng-cam, in treatment of nerve damage
US5567609A (en) * 1994-06-30 1996-10-22 University Of Kansas Medical Center Use of isolated domains of type IV collagen to modify cell and tissue interactions
EP0878480A1 (de) * 1997-05-14 1998-11-18 H.W. Prof. Dr. Müller Verfahren zur Förderung der Nerven-Regenerierung

Also Published As

Publication number Publication date
EP0981549B1 (de) 2002-09-25
DE69808281T3 (de) 2008-01-24
EP0981549B2 (de) 2007-06-27
DE69808281T2 (de) 2003-01-16
EP0981549B9 (de) 2008-02-27
WO1998051708A1 (en) 1998-11-19
AU7654298A (en) 1998-12-08
EP0878480A1 (de) 1998-11-18
DK0981549T3 (da) 2003-02-10
ATE224915T1 (de) 2002-10-15
ES2180175T3 (es) 2003-02-01
US20050118177A1 (en) 2005-06-02
US7208153B2 (en) 2007-04-24
ES2180175T5 (es) 2008-02-01
US20070231330A1 (en) 2007-10-04
US20020115598A1 (en) 2002-08-22
EP0981549A1 (de) 2000-03-01
DK0981549T4 (da) 2007-10-29

Similar Documents

Publication Publication Date Title
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATA122888A (de) Verfahren zur beherrschung des aufrollens einer papier- oder ähnlichen bahn
DE60044335D1 (de) 16-phenoxy-lipoxin analoge zur medizinischen verwendung
DE69326137D1 (de) Methode zur überwachung der regenerierung eines wasserbehandlungssystems
DE69328497D1 (de) Verfahren zur steigerung der wirksamkeit der futterverwertung bei tieren
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
ATE224915T1 (de) Verwendung einer inhibitorsubstanz zur förderung der neuronalen regeneration
DE69636451D1 (de) Verfahren zur korrosionsinhibierung unter verwendung von n-halo-azolen
DE50009908D1 (de) Verfahren zur farblichen Musterung einer Bahn mittels hydrodynamischer Behandlung
ATE267180T1 (de) Phosphorderivate zur behandlung von aids
DE69928139D1 (de) Verwendung einer Vorrichtung zur Erhöhung der Feuchtigkeit
DE59209268D1 (de) Verfahren zur thermochemisch-thermischen behandlung von einsatzstählen
DE69320801D1 (de) Verfahren zur überwachung des wachsamkeitniveaus einer person.
DE69500511D1 (de) Phosphatdiester zur Behandlung von proliferativen Erkrankungen der Epidermis
DE69604657D1 (de) Verwendung einer n-arylpyrazol- oder n-heteroarylpyrazolverbindung zur regulierung von pflanzenwachstum
DE59601439D1 (de) Verfahren zur Regelung einer Feuchtmittelmenge
ATE419346T1 (de) Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69607559D1 (de) Verfahren zur Behandlung von Phenolteer
DE69402849D1 (de) Verfahren zur uberwachung der justierung einer ziel-oder uberwachungssensorreihe
DE69622956D1 (de) Methode zur Regelung der Bestandteile eines Phosphatbades
DE59808452D1 (de) Verfahren zur Überwachung des Paraffinauftrags auf einen laufenden Faden
DE59000468D1 (de) Verfahren zur schnellen pruefung der wirksamkeit von agenzien auf mikroorganismen.
DE59509677D1 (de) Verfahren zur enzymatischen Spaltung von 2-Amino-4-methylphosphinobutansäureamid-Derivaten

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: NEURAXO BIOPHARMACEUTICALS GMBH, 40699 ERKRATH, DE

8366 Restricted maintained after opposition proceedings